BRIEF RESEARCH REPORT article
Front. Public Health
Sec. Disaster and Emergency Medicine
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1601926
This article is part of the Research TopicImplementation Science for Disaster Preparedness and Emergency MedicineView all 3 articles
Cost Savings of EMS Administration of Bronchodilators and Systemic Corticosteroids for Pediatric Asthma Patients
Provisionally accepted
- 1University of Florida, Gainesville, United States
- 2Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Pediatric asthma costs the United States healthcare system $5 billion annually. A major component of those costs are hospitalizations for acute exacerbations. This brief report examines the cost savings from emergency medical services (EMS) administration of bronchodilators and systemic corticosteroids to pediatric asthma patients, as opposed to waiting for emergency department (ED) arrival. Methods: This is an economic analysis of data from a study of seven EMS agencies who incorporated both bronchodilators and systemic corticosteroids in their standard operating protocols for all children ages 0 – 17 years experiencing an asthma exacerbation. Comparing hospital admission rates between children who did and did not receive those medications from EMS, we calculated the number needed to treat (NNT) to prevent one hospitalization, and using the most recently available cost estimate of a pediatric asthma hospitalization, we calculated cost savings for EMS administration of bronchodilators and systemic corticosteroids. Results: For all pediatric asthma patients, the NNT was 58.8, which would avert 1,913 hospitalizations nationwide and save $6,886,800. For mild severity exacerbations, the NNT was 9, and for patients with an EMS transport time longer than 40 minutes, the NNT was 6. If EMS administered bronchodilators and systemic corticosteroids to all mild severity exacerbation and prolonged transport time pediatric asthma patients, then 6,833 mild severity and 500 prolonged transport time patients could avert a hospitalization, resulting in savings of $26,398,800. Conclusion: EMS administration of bronchodilators and systemic corticosteroids results in cost savings, notably for mild severity patients and those with prolonged transport times.
Keywords: Asthma, Emergency Medical Services, pediatric asthma, pediatric emergency medicine, Systemic corticosteroids
Received: 28 Mar 2025; Accepted: 08 Aug 2025.
Copyright: © 2025 Fishe, Garvan, Riney, Finlay, Palmer and Hendry. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jennifer Fishe, University of Florida, Gainesville, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.